Header

UZH-Logo

Maintenance Infos

Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV/HCV-coinfected individuals


Rohrbach, Janine; Stickel, Felix; Schmid, Patrick; Thormann, Wolfgang; Kovari, Helen; Scherrer, Alexandra; Günthard, Huldrych F; Vuichard, Danielle; Cavassini, Matthias; Ambrosioni, Juan; Bernasconi, Enos; Furrer, Hansjakob; Rauch, Andri (2013). Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV/HCV-coinfected individuals. Antiviral Therapy, 19(2):149-159.

Abstract

BACKGROUND: We investigated changes in biomarkers of liver disease in HIV/HCV- coinfected individuals during successful combination antiretroviral therapy (cART) compared to changes in biomarker levels during untreated HIV-infection and to HIV-monoinfected individuals.
METHODS: Non-invasive biomarkers of liver disease [hyaluronic acid (HYA), APRI, FIB-4 and cytokeratin-18 (CK-18)] were correlated with liver histology in 49 HIV/HCV-coinfected patients. Changes in biomarkers over time were then assessed longitudinally in HIV/HCV-coinfected patients during successful cART (n=58), during untreated HIV-infection (n=59), and in HIV-monoinfected individuals (n=17). The median follow-up time was 3.4 years on-cART. All analyses were before starting HCV treatment.
RESULTS: Non-invasive biomarkers of liver disease correlated significantly with the histological METAVIR-stage (P<0.002 for all comparisons). The AUROC values for advanced fibrosis (≥F3-METAVIR) for HYA, APRI, FIB-4 and CK-18 were 0.86±0.05, 0.84±0.08, 0.80±0.09 and 0.81±0.07, respectively. HYA, APRI and CK-18 levels were higher in HIV/HCV-coinfected compared to HIV-monoinfected patients (P<0.01). In the first year on cART, APRI and FIB-4 scores decreased (-35% and -33%, P=0.1), mainly due to the reversion of HIV-induced thrombocytopenia, while HYA and CK-18 levels remained unchanged. During long-term cART, there were only small changes (<5%) in median biomarker levels. Median biomarker levels changed less than 3% during untreated HIV-infection. Three patients died from end-stage liver disease, and 10 from other causes.
CONCLUSIONS: Biomarkers of liver disease highly correlated with fibrosis in HIV/HCV-coinfected individuals and did not change significantly during successful cART. These findings suggest a slower than expected liver disease progression in many HIV/HCV-coinfected individuals, at least during successful cART.

Abstract

BACKGROUND: We investigated changes in biomarkers of liver disease in HIV/HCV- coinfected individuals during successful combination antiretroviral therapy (cART) compared to changes in biomarker levels during untreated HIV-infection and to HIV-monoinfected individuals.
METHODS: Non-invasive biomarkers of liver disease [hyaluronic acid (HYA), APRI, FIB-4 and cytokeratin-18 (CK-18)] were correlated with liver histology in 49 HIV/HCV-coinfected patients. Changes in biomarkers over time were then assessed longitudinally in HIV/HCV-coinfected patients during successful cART (n=58), during untreated HIV-infection (n=59), and in HIV-monoinfected individuals (n=17). The median follow-up time was 3.4 years on-cART. All analyses were before starting HCV treatment.
RESULTS: Non-invasive biomarkers of liver disease correlated significantly with the histological METAVIR-stage (P<0.002 for all comparisons). The AUROC values for advanced fibrosis (≥F3-METAVIR) for HYA, APRI, FIB-4 and CK-18 were 0.86±0.05, 0.84±0.08, 0.80±0.09 and 0.81±0.07, respectively. HYA, APRI and CK-18 levels were higher in HIV/HCV-coinfected compared to HIV-monoinfected patients (P<0.01). In the first year on cART, APRI and FIB-4 scores decreased (-35% and -33%, P=0.1), mainly due to the reversion of HIV-induced thrombocytopenia, while HYA and CK-18 levels remained unchanged. During long-term cART, there were only small changes (<5%) in median biomarker levels. Median biomarker levels changed less than 3% during untreated HIV-infection. Three patients died from end-stage liver disease, and 10 from other causes.
CONCLUSIONS: Biomarkers of liver disease highly correlated with fibrosis in HIV/HCV-coinfected individuals and did not change significantly during successful cART. These findings suggest a slower than expected liver disease progression in many HIV/HCV-coinfected individuals, at least during successful cART.

Statistics

Citations

6 citations in Web of Science®
7 citations in Scopus®
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Infectious Diseases
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2013
Deposited On:06 Nov 2013 15:03
Last Modified:05 Apr 2016 17:07
Publisher:International Medical Press
ISSN:1359-6535
Publisher DOI:https://doi.org/10.3851/IMP2686
PubMed ID:24036684

Download

Full text not available from this repository.
View at publisher

Article Networks

TrendTerms

TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents.
You can navigate and zoom the map. Mouse-hovering a term displays its timeline, clicking it yields the associated documents.

Author Collaborations